Suvro Sankha Datta1, Sabita Basu2, Mammen Chandy2. 1. Department of Transfusion Medicine, TATA Medical Center, Kolkata, West Bengal, India. Electronic address: suvro.datta@gmail.com. 2. Department of Transfusion Medicine, TATA Medical Center, Kolkata, West Bengal, India.
Abstract
BACKGROUND: Transfusion support in haematopoietic stem cell transplantation (HSCT) can be very demanding and challenging. The conditioning regimen, stem cell dose, donor type, presence of GvHD, infection all influence transfusion therapy in haematopoietic stem cell transplantation (HSCT). We retrospectively analysed the first 100 days transfusion requirements among HSCT recipients with haematological as well as non-haematological malignancies in our centre. MATERIALS AND METHODS: Transfusion data were retrieved for 100 patients who had undergone HSCT over a period of two years. The HSCT recipients were divided into three groups: autologous, allogenic and haplo-identical. Allogenic group was subdivided into matched related donor (MRD) and matched unrelated donor (MUD). The allo and haplo groups were then classified on the basis of the ABO compatibility as major, minor, bi-directional and compatible. We analysed the mean requirement of blood components (RBC, RDP, SDP and FFP) within the first 100 days of HSCT in each category. RESULTS AND DISCUSSION: Haematologic malignancies constituted 97% of the indications for HSCT. Allo-HSCT constituted 50% of the HSCT, of which 92% were MRD. Auto and haplo-HSCT constituted 40% and 10% respectively. Mean requirement for all products--RBC, SDP, RDP and FFP--was highest in the haplo category, followed by the allo category and then the auto HSCT category. The mean product requirement in the MUD category was significantly higher than in the MRD category (p < 0.05). The mean product requirement in the major and bidirectional ABO incompatible group was significantly higher as compared to the minor and ABO compatible group (p < 0.05). Hence our data may help transfusion medicine specialists to understand the transfusion requirement in stem cell transplant settings from developing countries like India. The average number of blood donors required for each group of stem cell transplant patients can also be roughly predicted from this study.
BACKGROUND: Transfusion support in haematopoietic stem cell transplantation (HSCT) can be very demanding and challenging. The conditioning regimen, stem cell dose, donor type, presence of GvHD, infection all influence transfusion therapy in haematopoietic stem cell transplantation (HSCT). We retrospectively analysed the first 100 days transfusion requirements among HSCT recipients with haematological as well as non-haematological malignancies in our centre. MATERIALS AND METHODS: Transfusion data were retrieved for 100 patients who had undergone HSCT over a period of two years. The HSCT recipients were divided into three groups: autologous, allogenic and haplo-identical. Allogenic group was subdivided into matched related donor (MRD) and matched unrelated donor (MUD). The allo and haplo groups were then classified on the basis of the ABO compatibility as major, minor, bi-directional and compatible. We analysed the mean requirement of blood components (RBC, RDP, SDP and FFP) within the first 100 days of HSCT in each category. RESULTS AND DISCUSSION: Haematologic malignancies constituted 97% of the indications for HSCT. Allo-HSCT constituted 50% of the HSCT, of which 92% were MRD. Auto and haplo-HSCT constituted 40% and 10% respectively. Mean requirement for all products--RBC, SDP, RDP and FFP--was highest in the haplo category, followed by the allo category and then the auto HSCT category. The mean product requirement in the MUD category was significantly higher than in the MRD category (p < 0.05). The mean product requirement in the major and bidirectional ABO incompatible group was significantly higher as compared to the minor and ABO compatible group (p < 0.05). Hence our data may help transfusion medicine specialists to understand the transfusion requirement in stem cell transplant settings from developing countries like India. The average number of blood donors required for each group of stem cell transplant patients can also be roughly predicted from this study.
Authors: Linda M Griffith; Mark VanRaden; A John Barrett; Richard W Childs; Daniel H Fowler; Elizabeth M Kang; John F Tisdale; Harvey G Klein; David F Stroncek Journal: Transfusion Date: 2018-10-26 Impact factor: 3.157